Mochida Pharmaceutical obtained drug marketing approval for Epadel T, indicated for triglyceride levels that are in the borderline region.
The ethical drugs Epadel were converted into an OTC drug to develop Epadel T, containing 600mg of EPA-E per packet.
Epadel is a prescription pharmaceutical treatment for hyperlipidemia and arteriosclerosis obliterans manufactured by Mochida.
Taisho will conduct a survey to find out the ability of pharmacists to identify costumers suitable for the product and during the survey period, the product will be made available only at drugstores participating in the survey.